by clearskymd | Jul 7, 2020 | Company News
We have launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor. Parkinson’s is the second most common neurodegenerative disorder and is characterised by bradykinesia – a slowness in carrying out movements....
by clearskymd | Feb 6, 2020 | Blog
We were delighted to be invited to showcase our technology and devices at a prestigious innovation exchange event in Leeds in January – MIT Reap. The event was part of an international programme that the city of Leeds was chosen to host, in partnership with one...
by clearskymd | Oct 31, 2019 | Parkinson's
Levodopa is one of the main medications used to treat symptoms of Parkinson’s. As Parkinson’s progresses the doses of levodopa needed to maintain control over symptoms increases. Dyskinesia is a complication of long-term levodopa use in people who have had...
by clearskymd | Oct 30, 2019 | Company News
ClearSky Medical Diagnostics is thrilled to announce that two LID-Monitors, designed to help people with Parkinson’s control their condition, have been acquired at a hospital in Leeds. Leeds Teaching Hospitals provides a comprehensive service for patients with...
by clearskymd | Jul 2, 2019 | Company News
A research paper describing some of the experimental work being undertaken in the development of ClearSky’s CF-Monitor will be presented at the MedGEC Workshop 2019 in Prague in July. The MedGEC Workshop focusses on the application of genetic and evolutionary...
Recent Comments